How Toyota are helping people to walk again
Toyotas Welwalk WW-1000 will begin roll-out in aut...
Hospitals in Japan will soon be welcoming robotic machinery to help those with lower-limb paralysis.
Toyota’s Welwalk WW-1000 will begin roll-out in autumn of this year and will be available to rent, but will cost £7,300 upfront as well as a monthly fee of £2,500.
The machinery attaches to the knee of the patient and enables those who have suffered from paralysis to walk again. Due to Japan’s aging population, this could be a crucial step as mobility problems rise and the machinery boasts that it can rehabilitate stroke victims 60% faster than normal physiotherapy.
The Welwalk is in line with a series of Toyota robots, who are being built to perform takes generally undertaken by care workers. Mundane tasks that are encountered with difficulty by those suffering could soon be performed by robotics counterparts as opposed to humans.
However, Toyota’s robot is currently only available in Japan and would have to be modified to cope with the physique of the western world, as the current model only supports 95kg of weight and those shorter than 6’3”.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”